Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal ...
View HTML
Toggle Summary RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia ® this quarter and the ongoing promotion of Aemcolo ® RedHill will receive an additional $50 million to fund the acquisition of rights to Movantik ® from AstraZeneca ...
View HTML
Toggle Summary RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca
RedHill to promote Movantik ® in the U.S. upon closing  Movantik ® generated U.S. net sales of $96 million in 2019 Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing    TEL-AVIV, Israel and RALEIGH, N.C. , Feb. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the 9th Annual SVB Leerink Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal ...
View HTML
Toggle Summary RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
RedHill is on track to launch Talicia ® in the U.S. in the first quarter of 2020 for the treatment of  H. pylori infection in adults - - - RedHill to sponsor H. pylori medical education event at the Pri-Med South Conference scheduled for February 6-9, 2020 - - - RedHill to sponsor the No Stomach ...
View HTML
Toggle Summary RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
View HTML
Toggle Summary RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
View HTML
Toggle Summary RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ Diarrhea
Aemcolo ®  (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestine Aemcolo ® is approved by the FDA for the treatment of travelers’ diarrhea, and is covered by a robust U.S. patent portfolio which, together with the U.S. ...
View HTML
Toggle Summary RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults   Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...
View HTML
Toggle Summary Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML